RT Journal Article
T1 The current status of COVID-19 vaccines. A scoping review.
A1 Rueda-Fernandez, Manuel
A1 Melguizo-Rodriguez, Lucia
A1 Costela-Ruiz, Victor J
A1 Gonzalez-Acedo, Anabel
A1 Ramos-Torrecillas, Javier
A1 Illescas-Montes, Rebeca
K1 Humans
K1 NVX-CoV2373 adjuvated lipid nanoparticle
K1 ChAdOx1 nCoV-19
K1 SARS-CoV-2
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.
PB Elsevier Ltd. * Trends Journals
YR 2022
FD 2022-08-19
LK http://hdl.handle.net/10668/22156
UL http://hdl.handle.net/10668/22156
LA en
NO Rueda-Fernández M, Melguizo-Rodríguez L, Costela-Ruiz VJ, González-Acedo A, Ramos-Torrecillas J, Illescas-Montes R. The current status of COVID-19 vaccines. A scoping review. Drug Discov Today. 2022 Nov;27(11):103336.
DS RISalud
RD Apr 12, 2025